Table 1.
Patients and Tumor Samples.
| Patient | Sample | Age at Surgery | Sex | Type of Sample | Primary Tumor Location | Tumor Size | Mitotic Index 50HPF | Source | Treatment Before Sampling | WES | RNA-Seq |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P01 | T01 | 62 | M | Frozen | stomach | 11 | 300 | metastasis | C, D | 101X1 | NA |
| P02 | T02 | 74 | F | Frozen | stomach | 16.2 | 5 | metastasis | C | 101X1 | NA |
| P03 | T03 | 51 | M | Frozen | stomach | 5 | 55 | metastasis | I, G/D, Su, IPI-504, So, STA-9090, D, GDC-0980, C | 101X1 | NA |
| P04 | T04 | 51 | M | FFPE | stomach | 6.2 | 7 | metastasis | none | 101X1 | NA |
| T05 | 51 | M | FFPE | stomach | 6.2 | 7 | metastasis | none | 101X1 | NA | |
| P05 | T06 | 53 | M | Frozen OCT | NA | NA | NA | primary | none | 101X1 | NA |
| P06 | T07 | 56 | M | FFPE | stomach | 30 | high | metastasis | I, Su, So, N | 101X1 | NA |
| T08 | 56 | M | FFPE | stomach | 30 | high | metastasis | I, Su, So, N | 101X1 | NA | |
| T09 | 56 | M | FFPE | stomach | 30 | high | metastasis | I, Su, So, N | 101X1 | NA | |
| T10 | 56 | M | FFPE | stomach | 30 | high | metastasis | I, Su, So, N | 101X1 | NA | |
| T11 | 56 | M | FFPE | stomach | 30 | high | metastasis | I, Su, So, N | 101X1 | NA | |
| P07 | T12 | 63 | F | Frozen | stomach | 10.5 | 19 | NA | C | 101X1 | NA |
| P08 | T13 | 76 | M | Frozen | stomach | NA | NA | primary | none | 101X1 | NA |
| P09 | T14 | 30 | M | Frozen | stomach | NA | NA | primary | none | 101X1 | NA |
| P10 | T15 | 50 | F | Frozen | stomach | 1.8 | 2 | primary | none | 100X2 | 75X2 |
| P11 | T16 | 75 | F | Frozen | stomach | 7 | 8 | primary | none | 100X2 | 75X2 |
| P12 | T17 | 68 | M | Frozen | stomach | 3 | 5 | primary | none | 100X2 | 75X2 |
| P13 | T18 | 76 | M | Frozen | stomach | 4.5 | 6 | primary | none | 100X2 | 75X2 |
| P14 | T19 | 51 | M | Frozen | stomach | 12 | 2 | primary | none | 100X2 | 75X2 |
WES, whole exome sequencing; FFPE, formalin-fixed paraffin-embedded; OCT, optimal cutting temperature; M, male; F, female (F); NA, Not Available; C, Crenolanib; D, dasatinib; I, imatinib; N, nilotinib; So, sorafenib; Su, sunitinib; GD, gemcitabine/docetaxel ; STA-9090, ganetespib; GDC-0980, apitolisib; IPI-504, retaspimycin.